FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N⁶-Methyladenosine RNA Demethylase

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• N6-Methyladenosine (m6A) is the most abundant internal modification in mammalian messenger RNAs (mRNAs).
• The role of m6A modifications and associated proteins in cancer, particularly acute myeloid leukemia (AML), remains underexplored.
• FTO functions as an m6A demethylase, suggesting potential involvement in regulatory pathways.

Purpose of the Study:

• To investigate the role of FTO and m6A demethylation in the pathogenesis of acute myeloid leukemia (AML).
• To determine the correlation between FTO expression and specific genetic mutations in AML.
• To elucidate the mechanism by which FTO influences leukemogenesis and AML cell differentiation.

Main Methods:

• Analysis of FTO expression in AML patient samples with specific genetic alterations.
• Assessment of FTO's impact on leukemic cell transformation and oncogenesis.
• Evaluation of FTO's effect on all-trans-retinoic acid (ATRA)-induced differentiation in AML cells.
• Quantification of m6A levels in target mRNA transcripts (ASB2, RARA) regulated by FTO.

Main Results:

• FTO is highly expressed in AML subtypes characterized by MLL rearrangements, PML-RARA, FLT3-ITD, and NPM1 mutations.
• FTO overexpression enhances oncogene-driven cell transformation and leukemogenesis.
• FTO inhibits ATRA-induced differentiation of AML cells.
• FTO reduces m6A levels in ASB2 and RARA mRNA, impacting their expression and downstream effects.

Conclusions:

• FTO plays a critical oncogenic role in AML through its function as an m6A demethylase.
• FTO-mediated regulation of m6A levels in target genes like ASB2 and RARA is crucial for leukemogenesis and differentiation.
• These findings highlight the significance of the m6A epitranscriptomic landscape in cancer and offer insights into potential therapeutic strategies for AML.